Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 16
Figure 4. North America Clinical Diagnostics Market, 2021-2031, $ mn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of North America Clinical Diagnostics Market 24
Figure 7. Leading Causes of Death in the World, 2019-2020, million 27
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060 28
Figure 10. Primary Restraints and Impact Factors of North America Clinical Diagnostics Market 30
Figure 11. Investment Opportunity Analysis 34
Figure 12. Porter’s Fiver Forces Analysis of North America Clinical Diagnostics Market 37
Figure 13. Breakdown of North America Clinical Diagnostics Market by Test, 2021-2031, % of Revenue 42
Figure 14. North America Addressable Market Cap in 2022-2031 by Test, Value ($ mn) and Share (%) 42
Figure 15. North America Clinical Diagnostics Market by Test: Lipid Panel, 2021-2031, $ mn 43
Figure 16. North America Clinical Diagnostics Market by Test: Infectious Disease Testing, 2021-2031, $ mn 44
Figure 17. North America Clinical Diagnostics Market by Test: Liver Panel, 2021-2031, $ mn 45
Figure 18. North America Clinical Diagnostics Market by Test: Complete Blood Count (CBC), 2021-2031, $ mn 46
Figure 19. North America Clinical Diagnostics Market by Test: Electrolyte Testing, 2021-2031, $ mn 47
Figure 20. North America Clinical Diagnostics Market by Test: Renal Panel, 2021-2031, $ mn 48
Figure 21. North America Clinical Diagnostics Market by Test: Other Tests, 2021-2031, $ mn 49
Figure 22. Breakdown of North America Clinical Diagnostics Market by Product, 2021-2031, % of Sales Revenue 51
Figure 23. North America Addressable Market Cap in 2022-2031 by Product, Value ($ mn) and Share (%) 51
Figure 24. North America Clinical Diagnostics Market by Product: Instruments, 2021-2031, $ mn 52
Figure 25. North America Clinical Diagnostics Market by Product: Assay Kits & Reagents, 2021-2031, $ mn 53
Figure 26. North America Clinical Diagnostics Market by Product: Software & Services, 2021-2031, $ mn 54
Figure 27. Breakdown of North America Clinical Diagnostics Market by Indication, 2021-2031, % of Sales Revenue 56
Figure 28. North America Addressable Market Cap in 2022-2031 by Indication, Value ($ mn) and Share (%) 56
Figure 29. North America Clinical Diagnostics Market by Indication: Cardiovascular, 2021-2031, $ mn 57
Figure 30. North America Clinical Diagnostics Market by Indication: Cancer, 2021-2031, $ mn 58
Figure 31. North America Clinical Diagnostics Market by Indication: Infectious Disease, 2021-2031, $ mn 59
Figure 32. North America Clinical Diagnostics Market by Indication: Stroke, 2021-2031, $ mn 60
Figure 33. North America Clinical Diagnostics Market by Indication: Chronic Lower Respiratory Diseases, 2021-2031, $ mn 61
Figure 34. North America Clinical Diagnostics Market by Indication: Diabetes, 2021-2031, $ mn 62
Figure 35. North America Clinical Diagnostics Market by Indication: Other Indications, 2021-2031, $ mn 63
Figure 36. Breakdown of North America Clinical Diagnostics Market by Patient Gender, 2021-2031, % of Revenue 65
Figure 37. North America Addressable Market Cap in 2022-2031 by Patient Gender, Value ($ mn) and Share (%) 65
Figure 38. North America Clinical Diagnostics Market by Patient Gender: Male Patients, 2021-2031, $ mn 66
Figure 39. North America Clinical Diagnostics Market by Patient Gender: Female Patients, 2021-2031, $ mn 67
Figure 40. Breakdown of North America Clinical Diagnostics Market by Age Group, 2021-2031, % of Revenue 69
Figure 41. North America Addressable Market Cap in 2022-2031 by Age Group, Value ($ mn) and Share (%) 69
Figure 42. North America Clinical Diagnostics Market by Age Group: Age 44 and below, 2021-2031, $ mn 70
Figure 43. North America Clinical Diagnostics Market by Age Group: Age 45-64, 2021-2031, $ mn 71
Figure 44. North America Clinical Diagnostics Market by Age Group: Age 65 and over, 2021-2031, $ mn 72
Figure 45. Breakdown of North America Clinical Diagnostics Market by End User, 2021-2031, % of Revenue 73
Figure 46. North America Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 74
Figure 47. North America Clinical Diagnostics Market by End User: Hospital & Clinics Laboratory, 2021-2031, $ mn 75
Figure 48. North America Clinical Diagnostics Market by End User: Diagnostic Laboratory, 2021-2031, $ mn 76
Figure 49. North America Clinical Diagnostics Market by End User: Point-of-Care Testing, 2021-2031, $ mn 77
Figure 50. North America Clinical Diagnostics Market by End User: Other End Users, 2021-2031, $ mn 78
Figure 51. Breakdown of North America Clinical Diagnostics Market by Country, 2021 and 2031, % of Revenue 80
Figure 52. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 81
Figure 53. U.S. Clinical Diagnostics Market, 2021-2031, $ mn 83
Figure 54. Percent Distribution of the 10 Leading Causes of Death by Gender in United States, 2019, % 83
Figure 55. Percent Distribution of the 10 Leading Causes of Death by Age Group in United States, 2019, % 84
Figure 56. Canada Clinical Diagnostics Market, 2021-2031, $ mn 86
Figure 57. Clinical Diagnostics Market in Mexico, 2021-2031, $ mn 88
Figure 58. Growth Stage of North America Clinical Diagnostics Industry over the Forecast Period 90
North America clinical diagnostics market is projected to grow by 6.6 % annually in the forecast period and reach $53,670.4 million by 2031, driven by the rising patient awareness and rising demand for high-quality care amid the COVID-19 pandemic, growing healthcare spend, technological advancement, benefits of clinical diagnostics such as quick test results and easy procedure, increasing prevalence of chronic diseases caused due to sedentary lifestyle such as diabetes, cardiovascular diseases, high blood pressure, lipid disorders, kidney diseases and cancer. Highlighted with 23 tables and 58 figures, this 108-page report “North America Clinical Diagnostics Market 2021-2031 by Test (Lipid Panel, Infectious Disease Testing, Liver Panel, CBC), Product (Instruments, Assay Kits & Reagents, Software & Services), Indication (Cardiovascular, Cancer, Infectious Disease), Patient Gender (Male, Female), Age Group (44 and below, 45-64, 65 and over), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America clinical diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America clinical diagnostics market in every aspect of the classification from perspectives of by Test, Product, Indication, Patient Gender, Age Group, End User, and Country. Based on Test, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Lipid Panel • Infectious Disease Testing • Liver Panel • Complete Blood Count (CBC) • Electrolyte Testing • Renal Panel • Other Tests Based on Product, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Instruments • Assay Kits & Reagents • Software & Services By Indication the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Cardiovascular • Cancer • Infectious Disease • Stroke • Chronic Lower Respiratory Diseases • Diabetes • Other Indications By Patient Gender the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Male Patients • Female Patients By Age Group the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Age 44 and below • Age 45-64 • Age 65 and over By End User the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Hospital & Clinics Laboratory • Diagnostic Laboratory • Point-of-Care Testing • Other End Users Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis, and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of key national markets by Test, Product, and Indication over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: • Abbott Laboratories • Becton, Dickinson and Company • BioMerieux SA • Bio-Rad Laboratories Inc. • Bio-Reference Laboratories • Bioscientia Healthcare • Charles River Laboratories • Danaher Corporation • Hoffmann-La Roche AG • Hologic Inc. • Qiagen NV • Siemens Healthcare • Thermo Fisher Scientific (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More